Knockdown of Y-box-binding protein-1 inhibits the malignant progression of HT-29 colorectal adenocarcinoma cells by reversing epithelial-mesenchymal transition

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2720-2728

  Yan, Xue Bing ^a   Zhu, Qing Chao ^a   Chen, Hong Qi ^a   Peng, Jia Yuan ^a   Chao, Hong Lei ^a   Du, Hang Xiang ^a   Wang, Zhi Gang ^a   Jin, Zhi Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colorectal cancer; Epithelial mesenchymal transition; Invasion; Metastasis; YB 1

Indexed keywords

BETA ACTIN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UVOMORULIN; VIMENTIN; Y BOX BINDING PROTEIN 1; YBX1 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HT 29 CELL LINE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR INVASION; ADENOCARCINOMA; BIOSYNTHESIS; CELL MOTION; COLORECTAL TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADENOCARCINOMA; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; Y-BOX-BINDING PROTEIN 1;

EID: 84907198966     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2545     Document Type: Article

References (37)

1. Garcia-Albeniz X and Chan AT: Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol 25: 461-472, 2011.
2. Lasham A, Samuel W, Cao H, et al: YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst 104: 133-146, 2012.
3. Bommert KS, Effenberger M, Leich E, et al: The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia 27: 441-450, 2013.
4. Takahashi M, Shimajiri S, Izumi H, et al: Y-box binding protein-1 is a novel molecular target for tumor vessels. Cancer Sci 101: 1367-1373, 2010
5. Lovett DH, Cheng S, Cape L, Pollock AS and Mertens PR: YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun 398: 482-488, 2010.
6. Choi YK, Cho SG, Choi HS, Woo SM, Yun YJ, Shin YC and Ko SG: JNK1/2 activation by an extract from the roots of Morus alba L. reduces the viability of multidrug-resistant MCF-7/Dox cells by inhibiting YB-1-dependent MDR1 expression. Evid Based Complement Alternat Med 2013: 741985, 2013.
7. Wu Y, Yamada S, Izumi H, et al: Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol 105: 724-730, 2012.
8. Panupinthu N, Yu S, Zhang D, et al: Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene: Jul 15, 2013 (Epub ahead of print).
9. Imada K, Shiota M, Kohashi K, et al: Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res 19: 4638-4650, 2013.
10. Khan MI, Adhami VM, Lall RK, et al: YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget 5: 2462-2474, 2014.
11. Zhang H, Cheng S, Zhang M, et al: Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. Int J Oncol 44: 769-780, 2014.
12. Franco-Chuaire ML, Magda Carolina SC and Chuaire-Noack L: Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin 54: 186-205, 2013.
13. David JM and Rajasekaran AK: Dishonorable discharge: The oncogenic roles of cleaved E-cadherin fragments. Cancer Res 72: 2917-2923, 2012.
14. He X, Chen Z, Jia M and Zhao X: Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: Evidence from meta-analysis. PLoS One 8: E70858, 2013.
15. Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A and Kusunoki M: Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis: 34: 2548-2557, 2013.
16. Todosi AM, Gavrilescu MM, Aniţei GM, Filip B and Scripcariu V: Colon cancer at molecular level - usefulness of epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med Nat Iasi 116: 1106-1111, 2012.
17. Evdokimova V, Tognon C, Ng T, et al: Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15: 402-415, 2009.
18. Shiota M, Yokomizo A, Itsumi M, et al: Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells. BJU Int 108: E142-E149, 2011.
19. Matsushita K, Toiyama Y, Tanaka K, et al: Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol 19 (Suppl 3): S518-S527, 2012.
20. Tang FY, Pai MH and Chiang EP: Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model. J Nutr Biochem 23: 1302-1313, 2012.
21. Wu HM, Cao W, Ye D, Ren GX, Wu YN and Guo W: Contactin 1 (CNTN1) expression associates with regional lymph node metastasis and is a novel predictor of prognosis in patients with oral squamous cell carcinoma. Mol Med Rep 6: 265-270, 2012.
22. Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22: 194-207, 2012.
23. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P and Goldin R: Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol 21: 316-323, 2012.
24. Zhu QC, Gao RY, Wu W and Qin HL: Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev 14: 2689-2698, 2013.
25. Lasham A, Print CG, Woolley AG, Dunn SE and Braithwaite AW: YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J 449: 11-23, 2013.
26. Tsofack SP, Garand C, Sereduk C, et al: NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines. Mol Cancer 10: 145, 2011.
27. Jürchott K, Kuban RJ, Krech T, et al: Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet 6: E1001231, 2010.
28. Hsieh AC, Liu Y, Edlind MP, et al: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485: 55-61, 2012.
29. Schittek B, Psenner K, Sauer B, et al: The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120: 2110-2118, 2007.
30. Sinnberg T, Sauer B, Holm P, Spangler B, Kuphal S, Bosserfhoff A and Schittek B: MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp Dermatol 21: 265-270, 2012.
31. Di Costanzo A, Troiano A, di Martino O, et al: The p63 protein isoform δNp63α modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes. J Biol Chem 287: 30170-30180, 2012.
32. To K, Fotovati A, Reipas KM, et al: Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 70: 2840-2851, 2010.
33. Cho SH, Park YS, Kim HJ, et al: CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 41: 211-218, 2012.
34. Fujiwara-Okada Y, Matsumoto Y, Fukushi J, et al: Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer 108: 836-847, 2013.
35. Evdokimova V, Tognon C, Ng T and Sorensen PH: Reduced proliferation and enhanced migration: Two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 8: 2901-2906, 2009.
36. Mouneimne G and Brugge JS: YB-1 translational control of epithelial-mesenchyme transition. Cancer Cell 15: 357-359, 2009.
37. Guo TT, Yu YN, Yip GW, Matsumoto K and Bay BH: Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro. Anat Rec (Hoboken) 296: 891-898, 2013.